RO7795081

RO7795081 is an investigational oral small molecule drug developed by Roche (Genentech) for the treatment of obesity and metabolic disorders. It is currently being evaluated in Phase 1 clinical trials to assess its safety, pharmacokinetics, and interactions with other medications such as pitavastatin, rosuvastatin, itraconazole, gemfibrozil, and cyclosporine in healthy volunteers and overweight or obese adults. The precise mechanism of action has not been publicly disclosed; however, based on its development context within Roche’s metabolic pipeline and trial design focus on obesity/metabolic disease populations, it is likely a targeted therapy for weight management or related metabolic pathways[1][5][9]. No further molecular target information has been released.